Outcomes of ABO-Incompatible Living Donor Kidney Transplantation Compared to Waiting or Deceased Donor Kidney Transplantation
American Journal of Nephrology · 2024 · 55 (2) · 235-244
DOI: 10.1159/000535583 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 30.11.2023. Verfasst von Tai Yeon Koo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
ABO-incompatible (ABOi) living donor kidney transplantation (LDKT) is considered only for patients who do not have an ABO-compatible (ABOc) LD. Therefore, a clinically practical question is whether to proceed with ABOi LDKT or remain on dialysis while waiting for ABOc deceased donor kidney transplantation (DDKT). However, this issue has not been addressed in Asian countries, where ABOi LDKT programs are more active than DDKT programs.
Methods
A total of 426 patients underwent ABOi-LDKT between 2010 and 2020 at Seoul National University Hospital and Severance Hospital, Korea. We compared outcomes between the ABOi-LDKT and the propensity-matched control groups (waiting-list-only group, n = 1,278; waiting-list-or-ABOc-DDKT group, n = 1,278).
Results
The ABOi-LDKT group showed a significantly better patient survival rate than the waiting-list-only group (p = 0.001) and the waiting-list-or-ABOc-DDKT group (p = 0.048). When the ABOi-LDKT group was categorized into a high-titer group (peak anti-ABO titer ≥1:128) and a low-titer group (peak anti-ABO titer ≤1:64), the low-titer group showed better patient survival rates than those of the waiting-list-or-ABOc-DDKT group (p = 0.046) or the waiting-list-only group (p = 0.004). In contrast, the high-titer ABOi-LDKT group showed no significant benefit in patient survival compared to the waiting-list-or-ABOc-DDKT group. Death-censored graft survival in the ABOi-LDKT group was not significantly different from that in the ABOc-DDKT group (p = 0.563).
Conclusion
The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.
- Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
- The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Hanyang University Guri Hospital, Gyeonggi-do, Republic of Korea.
- Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Zitieren
APA
Koo, T. Y., Lee, J., Lee, Y., Kim, H. W., Kim, B. S., Huh, K. H., & Yang, J. (2024). Outcomes of ABO-Incompatible Living Donor Kidney Transplantation Compared to Waiting or Deceased Donor Kidney Transplantation. American Journal of Nephrology, 55(2), 235-244. https://doi.org/10.1159/000535583
Vancouver
Koo TY, Lee J, Lee Y, Kim HW, Kim BS, Huh KH, et al. Outcomes of ABO-Incompatible Living Donor Kidney Transplantation Compared to Waiting or Deceased Donor Kidney Transplantation. American Journal of Nephrology. 2024;55(2):235-244. doi:10.1159/000535583
BibTeX
@article{Koo2024,
author = {Koo, Tai Yeon and Lee, Juhan and Lee, Yonggu and Kim, Hyung Woo and Kim, Beom Seok and Huh, Kyu Ha and Yang, Jaeseok},
title = {Outcomes of ABO-Incompatible Living Donor Kidney Transplantation Compared to Waiting or Deceased Donor Kidney Transplantation},
journal = {American Journal of Nephrology},
year = {2024},
volume = {55},
number = {2},
pages = {235--244},
doi = {10.1159/000535583}
}
EUVIMED